Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26

Mumbai (Maharashtra) [India], November 11: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and animal healthcare products, has reported its Unaudited financials for Q2 FY26 & H1 FY26. Key Financial Highlights Q2 FY26 Standalone Financial Highlights • Total Income [...]

PNN
PNN Verified Media or Organization • 16 Apr, 2026 Agency
Nov 11, 2025 • 6:30 PM  0
B
Business
NEWS CARD
Logo
Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26
“Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26”
Favicon
Read more on en.sangritimes.com
11 Nov 2025
https://en.sangritimes.com/spotlight/fredun-pharmaceuticals-reports-61-percent-yoy-growth-in-ebitda-to-inr-3933-cr-in-h1-fy26
Copied
Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26
Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26

Mumbai (Maharashtra) [India], November 11: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and animal healthcare products, has reported its Unaudited financials for Q2 FY26 & H1 FY26.

Key Financial Highlights

rss_feed Disclaimer
Story published through syndicated feed.
favorite Follow us for the latest updates:

PNN Verified Media or Organization • 16 Apr, 2026 Agency

Agency

Digital Archives

Recommended Posts

home Home amp_stories Web Stories local_fire_department Trending play_circle Videos mark_email_unread Newsletter